Nuwellis Inc
Officers & Directors
Nestor Jaramillo Jr President and Chief Executive Officer Robert Scott Chief Financial Officer John L. Erb Chairman of the Board and Director Gregory D. Waller Director Archelle Georgiou, M.D. Director Mike McCormick Director Maria Rosa Costanzo Director Dave McDonald Director ,
Nuwellis Inc currently has 38 employees.
News about Nuwellis Inc Key Personnel |
Nuwellis, Inc.: Leadership Transition Amidst Financial Growth and Strategic Vision for the FutureIn a transformative period for Nuwellis, Inc. a key player in the medical technology industry, the company recently announced the retirement of Nestor Jaramillo, Jr. as President and CEO. In a corresponding move, John Erb, the current Chair of the Board, has been appointed as the Interim President and CEO, heralding a new chapter in the company s leadership.Jaramillo leaves behind a legacy that has significantly shaped Nuwellis’s trajectory in developing solutions for fluid overload in patients—an area where the need for innovative medical technology has never been more critical. His tenure was marked by a co...
|
In a move destined to reshape its financial outlook, Nuwellis Inc. announced a staggering 397% daily increase in the reimbursement rate for its Aquadex SmartFlow Therapy, effective January 1, 2025, from the Centers for Medicare and Medicaid Services (CMS). This monumental improvement comes on the heels of a more modest, but still impressive, 112.88% increase over the trailing 30 days. This development signals a potentially transformative shift for a company facing significant financial headwinds.Despite these encouraging changes in reimbursement, Nuwellis has been grappling with substantial fiscal challenges. The company recorded a cumulative net loss of $20 million during the twelve months ending in the sec...
|
Nuwellis Announces Pricing of $2.0 Million Offering to Fuel Growth in Fluid Overload Treatment Sector
MINNEAPOLIS, July 24, 2024 - Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, has recently closed a successful public offering to raise $2.0 million. The offering, priced at-the-market under Nasdaq rules, involved the purchase and sale of 469,340 shares of the Company s common stock to certain institutional investors.
This recent development represents a significant step forward for Nuwellis, as it seeks to address the growing needs of individuals suffering from fluid overload. The company has been dedicated to finding innova...
|
MINNEAPOLIS, May 09, 2024 - Nuwellis, Inc. (Nasdaq: NUWE), a leading medical technology company specializing in fluid overload treatment, has recently finalized a purchase agreement with one of the top 25 largest integrated delivery networks (IDN) in the United States. This collaboration marks a significant milestone for Nuwellis as it expands its reach and impact within the healthcare industry.
Under the new agreement, Nuwellis will provide its innovative Aquadex Ultrafiltration Therapy to a network of 50 hospitals. Aquadex is a proven technology that is transforming the lives of patients suffering from fluid overload. This therapy uses a gentle, adjustable method to remove excess fluid from t...
|
Nuwellis, Inc., a company dedicated to improving the lives of individuals suffering from fluid overload, recently released new real-world data highlighting the clinical benefits of using ultrafiltration therapy with hematocrit monitoring for pediatric patients. The data demonstrates that the hematocrit sensor within the Nuwellis Aquadex system offers unique advantages for fluid overloaded small patients.
This significant development comes at a crucial time for Nuwellis Inc, as the company s year-to-date performance has been challenging. In the 12 months ending in the third quarter of 2023, Nuwellis Inc recorded a cumulative net loss of $17 million, resulting in a negative return on assets of -94.65%...
|
|
|
